This month’s focus on pharmaphorum is clinical trials, so who better to share their view on global clinical trials than Zheng Su, Editor-in-Chief of the Contemporary Clinical Trials journal.

NetraMark Holdings ( ($TSE:AIAI) ) just unveiled an update. NetraMark has announced the launch of NetraAI 2.0, an advanced platform aimed at ...

Targeted Variable Analysis: Identify hard-to-detect combinations ... Delivering Key Benefits for Your Trials Enhanced Efficacy: Optimize key clinical endpoints with high effect-size models for ...

Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...

Some clinicians prefer aspirin when balancing bleeding risk with the indication for an anticoagulant, Barnes said, reasoning ...

Advertisement Article continues below this ad Yet, this lack of bespoke options is more or less the reality of medicine today. Despite the many biological differences between people of different ...

Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets for high-quality clinical trials have been recognised as robust and ...

In a systematic review and meta-analysis of trials of non-vitamin K oral anticoagulants vs. single antiplatelet therapy, ...

By transforming clinical trial data into actionable insights ... by assessing stability and variability across patient populations. Targeted Variable Analysis: Identify hard-to-detect combinations of ...

Targeted Variable Analysis: Identify hard-to-detect combinations of key ... Delivering Key Benefits for Your Trials Enhanced Efficacy: Optimize key clinical endpoints with high effect-size models for ...